Regencell Bioscience (RGC) had the highest return on April 1 by a mid-cap US stock, returning 34.4%.

ASSET	DATE	% RETURN
Regencell Bioscience (RGC)	4/1/2026	34.45%
Avis Budget (CAR)	4/1/2026	15.29%
Biohaven (BHVN)	4/1/2026	14.8%
Maase (MAAS)	4/1/2026	10.54%
Constellium (CSTM)	4/1/2026	9.28%
Kodiak Sciences (KOD)	4/1/2026	7.62%
Definium Therapeutics (DFTX)	4/1/2026	7.07%
BillionToOne, Inc Class A Common Stock (BLLN)	4/1/2026	6.85%
MBX Biosciences, Inc Common Stock (MBX)	4/1/2026	6.57%
VinFast Auto Ltd Ordinary Shares (VFS)	4/1/2026	6.49%
Relay Therapeutics (RLAY)	4/1/2026	6.42%
Century Aluminum (CENX)	4/1/2026	6.26%
Snap (SNAP)	4/1/2026	6.06%
PVH (PVH)	4/1/2026	5.97%
Planet Labs PBC (PL)	4/1/2026	5.9%
Brookfield Business (BBUC)	4/1/2026	5.49%
Liberty Global PLC Class B (LBTYB)	4/1/2026	5.38%
Mobileye Global Inc Class A Common Stock (MBLY)	4/1/2026	5.27%
Pulse Biosciences (PLSE)	4/1/2026	4.87%
Gates Industrial (GTES)	4/1/2026	4.82%
Travere Therapeutics (TVTX)	4/1/2026	4.8%
Pharvaris (PHVS)	4/1/2026	4.43%
Telephone and Data Systems (TDS)	4/1/2026	4.42%
SSR Mining (SSRM)	4/1/2026	4.41%
Bath & Body Works (BBWI)	4/1/2026	4.15%

Mid-cap stocks are treated as having a market cap between $2B and $10B.